{
  "_id": "bladder_trial_001",
  "title": "Adjuvant Immunotherapy for Muscle-Invasive Bladder Cancer",
  "full_text": "Key inclusion criteria: (1) Histologically confirmed muscle-invasive urothelial carcinoma of the bladder (pT2-pT4a and/or pN+). (2) Underwent radical cystectomy with curative intent within 120 days prior to enrollment. (3) Pathologically confirmed R0 resection (negative surgical margins). (4) Age ≥18 years. (5) ECOG performance status 0-1. (6) Adequate organ function defined as: absolute neutrophil count ≥1,500/μL, platelets ≥100,000/μL, hemoglobin ≥9 g/dL, serum creatinine ≤2.0 x ULN or creatinine clearance ≥30 mL/min, AST/ALT ≤2.5 x ULN, total bilirubin ≤1.5 x ULN. (7) Received neoadjuvant cisplatin-based chemotherapy OR ineligible for cisplatin-based adjuvant chemotherapy. (8) Written informed consent obtained. Key exclusion criteria: (1) Metastatic disease (M1) at any time point. (2) Prior systemic immunotherapy for urothelial carcinoma. (3) Active autoimmune disease requiring systemic immunosuppressive therapy. (4) History of organ transplant requiring immunosuppressive therapy. (5) Active infection requiring systemic therapy. (6) Known HIV infection with CD4 count <350. (7) Active hepatitis B or C infection. (8) Pregnancy or breastfeeding. (9) History of severe hypersensitivity to monoclonal antibodies. (10) Received live vaccine within 30 days of planned treatment start. (11) Concurrent malignancy requiring active treatment (excluding non-melanoma skin cancer, in situ cervical cancer). (12) Known brain metastases. (13) History of interstitial lung disease."
}
